Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.
Zhao
Zhengshan
Z
Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong, Seodaemoon-Ku, Seoul, Republic of Korea.
Lee
Yong-Jik
YJ
Kim
Soo-Kyung
SK
Kim
Hae-Jin
HJ
Shim
Wan-Sub
WS
Ahn
Chul-Woo
CW
Lee
Hyun-Chul
HC
Cha
Bong-Soo
BS
Ma
Zhongmin Alex
ZA
D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000818:Animals; D001835:Body Weight; D003921:Diabetes Mellitus, Experimental; D004032:Diet; D011345:Fenofibrate / Q000378:metabolism*; D005951:Glucose Tolerance Test; D007004:Hypoglycemic Agents / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000378:metabolism; D007328:Insulin / Q000378:metabolism*; D007333:Insulin Resistance; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008297:Male; D008316:Malonyl Coenzyme A / Q000378:metabolism*; D018482:Muscle, Skeletal / Q000166:cytology / Q000378:metabolism*; D051381:Rats; D020334:Rats, Inbred OLETF; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000378:metabolism*
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008316:Malonyl Coenzyme A; D055372:AMP-Activated Protein Kinases; D011345:Fenofibrate